FDA issues EUA for Eli Lilly’ monoclonal antibody COVID-19 treatment
The Food and Drug Administration Nov. 10 issued an for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab.
The EUA authorizes the product’s use, but only in outpatient settings; additionally, it sets forth the type of patients eligible to receive the treatment, the drug’s storage requirements and a brief overview of how distribution will work.
Operation Warp Speed will begin to distribute nearly 80,000 vials of this therapy today, with most hospitals anticipated to receive their allocation tomorrow or Thursday.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…